Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361755 | 0.84 | DRD2 (0.56) | KDM4EALDH1A1HPGDDRD2HTR2A | |
| SCHEMBL3143358 | 0.83 | CDK2 (0.57) | KDM4EALDH1A1HPGDDRD2HTR2A | |
| SCHEMBL1192525 | 0.82 | BRAF (0.53) | — | |
| SCHEMBL5416533 | 0.81 | CLK4 (0.52) | KDM4EMEN1KMT2AVNN1 | |
| SCHEMBL22792723 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL5207658 | 0.79 | CLK4 (0.51) | KDM4EALDH1A1CDK2 | |
| SCHEMBL22792358 | 0.78 | CDK2 (0.64) | ALDH1A1CDK2 | |
| SCHEMBL209726 | 0.77 | ALDH1A1 (0.53) | ALDH1A1HPGDDRD2VNN1 | |
| SCHEMBL1678795 | 0.76 | LTA4H (0.53) | ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL6283187 | 0.75 | MAP4K4 (0.48) | MEN1KMT2ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1671696-B | Kinase inhibitors | YM BIO SCIENCE AUSTRALIA PRIVATE CO LTD | 2010-12-08 | — | — | CN | disclosed |
| EP-1511742-B1 | KINASE INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2010-02-03 | — | — | EP | disclosed |
| EP-1511742-B1 | KINASE INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2010-02-03 | — | — | EP | disclosed |
| US-7598272-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-7598272-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-7598272-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-7511047-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-31 | — | — | US | disclosed |
| US-7511047-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-31 | — | — | US | disclosed |
| US-7511047-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-31 | — | — | US | disclosed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | disclosed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | disclosed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | disclosed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | disclosed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | disclosed |
| US-20060270687-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-11-30 | — | — | US | disclosed |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-10-26 | — | — | US | disclosed |
| CN-1671696-A | Kinase inhibitors | CYTOPIA PTY LTD (AU) | 2005-09-21 | — | — | CN | disclosed |
| EP-1511742-A1 | KINASE INHIBITORS | Cytopia PTY Ltd (AU) | 2005-03-09 | — | — | EP | disclosed |
| US-20050004140-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2005-01-06 | — | — | US | disclosed |
| WO-2003099811-A1 | KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270687-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | KDM4E 1738/4885ALDH1A1 3238/4885HPGD 3512/4885 |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | MAP4K2, MAP4K5, MAP4K4 | KDM4E 1505/4885ALDH1A1 3757/4885HPGD 3545/4885 |
| US-20050004140-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | KDM4E 1738/4885ALDH1A1 3238/4885HPGD 3512/4885 |
| US-20070161635-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K10 | KDM4E 2364/4885ALDH1A1 3695/4885HPGD 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.